- Home
- HKPD vs HBIO Comparison
HKPD vs HBIO Comparison
Compare HKPD & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKPD
- HBIO
- Stock Information
- Founded
- HKPD 2016
- HBIO 1901
- Country
- HKPD Hong Kong
- HBIO United States
- Employees
- HKPD N/A
- HBIO N/A
- Industry
- HKPD Other Pharmaceuticals
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- HKPD Health Care
- HBIO Industrials
- Exchange
- HKPD Nasdaq
- HBIO Nasdaq
- Market Cap
- HKPD 20.9M
- HBIO 24.6M
- IPO Year
- HKPD 2025
- HBIO 2000
- Fundamental
- Price
- HKPD $1.07
- HBIO $0.53
- Analyst Decision
- HKPD
- HBIO Buy
- Analyst Count
- HKPD 0
- HBIO 2
- Target Price
- HKPD N/A
- HBIO $3.00
- AVG Volume (30 Days)
- HKPD 70.4K
- HBIO 793.7K
- Earning Date
- HKPD 01-01-0001
- HBIO 08-11-2025
- Dividend Yield
- HKPD N/A
- HBIO N/A
- EPS Growth
- HKPD N/A
- HBIO N/A
- EPS
- HKPD 0.21
- HBIO N/A
- Revenue
- HKPD $20,770,344.00
- HBIO $88,750,000.00
- Revenue This Year
- HKPD N/A
- HBIO N/A
- Revenue Next Year
- HKPD N/A
- HBIO $9.75
- P/E Ratio
- HKPD $4.97
- HBIO N/A
- Revenue Growth
- HKPD 32.91
- HBIO N/A
- 52 Week Low
- HKPD $0.81
- HBIO $0.28
- 52 Week High
- HKPD $3.79
- HBIO $3.27
- Technical
- Relative Strength Index (RSI)
- HKPD N/A
- HBIO 57.04
- Support Level
- HKPD N/A
- HBIO $0.47
- Resistance Level
- HKPD N/A
- HBIO $0.54
- Average True Range (ATR)
- HKPD 0.00
- HBIO 0.04
- MACD
- HKPD 0.00
- HBIO 0.00
- Stochastic Oscillator
- HKPD 0.00
- HBIO 90.83
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.